AEMD

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. Management is executing a dual-track strategy focused on advancing the Hemopurifier platform in oncology while maintaining disciplined cost control to preserve capital. The Australian oncology trial has progressed to its third and final cohort, with the first participant already treated and monitored through a two-month follow-up period. Preliminary biomarker observations from Cohort 2 show more consistent and persistent reductions in tumor-derived extracellular vesicles (EVs) compared to the single-treatment Cohort 1. Operational efficiency was highlighted by an 11.9% decrease in operating expenses, driven by lower professional fees and reduced general and administrative costs. Strategic positioning is being broadened through preclinical research into Long COVID, lupus, and heart disease, leveraging the Hemopurifier's ability to bind to disease-implicated EVs. The company successfully strengthened its balance sheet post-quarter end with a $4 million public offering to support ongoing clinical and research activities. Management aims to complete all Hemopurifier treatments and the 8-week follow-up period for the Australian oncology trial by the end of calendar year 2026. Post-trial milestones include data analysis, completion of a clinical study report, and preregistration discussions with regulatory authorities. The company believes its current cash resources, including the recent capital raise, are sufficient to fund operations for at least the next 12 months. Future clinical development in areas like Long COVID may depend on securing academic partnerships, government grants, or potential expansions of the FDA's breakthrough device designation. Management expects to perform independent formal statistical analyses, including a dose-response analysis, once the full oncology trial data set is available. Peer-reviewed data published in June 2026 supports the Hemopurifier's ability to remove EVs associated with immune dysregulation in Long COVID patients. Management explicitly cautioned that current biomarker observations are preliminary, based on limited participants, and do not yet constitute evidence of safety or clinical benefit. The oncology trial requires the successful treatment of two additional participants without serious adverse events to reach completion. Aethlon is exploring the possibility of 'emergency use' one-off treatments for Long COVID if regulatory agencies broaden the current breakthrough device designation. One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here. Management observed that Cohort 2 (two treatments) showed positive directional changes in biomarkers lasting up to 8 weeks, whereas Cohort 1 (one treatment) lasted only 2-3 weeks. The biological signal appears more consistent across participants in the multi-dose cohort, suggesting a potential dose-response relationship that Cohort 3 will further test. Management clarified that they will not exceed three treatments per week due to patient tolerability and logistical constraints. A three-treatment-per-week schedule is considered the maximum feasible limit, mirroring standard hemodialysis protocols, and would likely be the strategy for future efficacy trials. The company utilizes in-house scientists and equipment to conduct preclinical research on new indications to minimize external spending. Management acknowledged that while internal research creates optionality, moving into human clinical trials for new indications like lupus or heart disease would require external capital or a strategic partner.

Conference Call Today at 4:30 p.m. ET SAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (Nasdaq: AEMD), a clinical-stage medical therapeutic company, today announced financial results for fiscal first quarter ended June 30, 2026, and provided a corporate update. "We advanced our clinical and research programs during the quarter," said James Frakes, CEO and CFO. "We treated the first participant in the third and final dosing cohort of our Phase 1 oncology study in Australia, and early biomarker signals from the initial cohorts support continuing evaluation of the Hemopurifier. We also had a Long COVID manuscript accepted for publication, which strengthens the scientific case for studying extracellular vesicles in post-viral conditions." Clinical highlights Phase 1 oncology study: First participant dosed in the third and final cohort in Australia. Early observations from the first two cohorts showed consistent decreases in tumor-derived extracellular vesicles and microRNAs linked to cancer progression and improvements in immune fumction associated with potential response to immunotherapy. These observations are preliminary and will be evaluated fully after study completion. Long COVID publication: A manuscript describing extracellular vesicle characteristics in patients with Long COVID was accepted for publication in the International Journal of Molecular Sciences. The manuscript demonstrates that the extracellular vesicles isolated from the plasma of individuals with Long COVID bind to the proprietary GNA affinity resin in the Hemopurifier. Financial highlights Cash and liquidity: Cash and cash equivalents were approximately $4.9 million as of June 30, 2026. Post-quarter financing: Subsequent to quarter-end, Aethlon raised approximately $4.0 million in gross proceeds through a public offering of common stock. Based on current plans, the company believes its cash resources are sufficient to fund operations for at least the next 12 months. Operating expenses: Consolidated operating expenses for the quarter decreased 11.9% to approximately $1.6 million versus $1.8 million in the prior-year quarter, driven by lower professional fees and reduced general and administrative and preclinical research costs. Operating loss declined accordingly. The consolidated balance sheets for June 30, 2026, and March 31, 2026 and the consolidated statements of operations for the fiscal quarters ended June 30, 2026, and 2025, are included at the end of this release. Conference Call Management will host a conference call today, Thursday, August 13, 2026, at 4:30 p.m. ET to review the Company's financial results and recent corporate developments. Following management's formal remarks, there will be a question-and-answer session. Interested parties can register for the conference call by navigating to https://dpregister.com/sreg/10211144/104a3acc428. Please note that registered participants will receive their dial-in number upon registration. Interested parties without internet access or unable to pre-register may dial in by calling: PARTICIPANT DIAL IN (TOLL FREE): 1-844-836-8741PARTICIPANT INTERNATIONAL DIAL IN: 1-412-317-5442 All callers should ask for the Aethlon Medical, Inc. conference call. A replay of the call will be available approximately one hour after the end of the call through September 13, 2026. The replay can be accessed via Aethlon Medical's website or by dialing 1-855-669-9658 (USA or Canada) or 1-412-317-0088 (international) or Canada toll free at 1-855-669-9658. The replay conference ID number is 6711524. About the Hemopurifier® The Aethlon Hemopurifier is an investigational medical device designed to remove enveloped viruses and tumor-derived extracellular vesicles (EVs) from circulation. It is used extracorporeally with a blood pump and combines plasma separation, size exclusion, and affinity binding using a plant lectin resin that targets mannose-rich surfaces found on EVs and viruses. EVs released by solid tumors are believed to play a role in metastasis and the resistance to immunotherapies and chemotherapy. Removal of enveloped viruses and extracellular vesicles has been demonstrated in both in vitro studies and human subjects. The Hemopurifier holds a U.S. Food and Drug Administration Breakthrough Device Designation for: The treatment of individuals with advanced or metastatic cancer unresponsive to or intolerant of standard-of-care therapy; and the treatment of life-threatening viruses not addressed with approved therapies. About Aethlon Medical, Inc. Aethlon Medical, Inc. (Nasdaq: AEMD) is a clinical-stage medical therapeutic company headquartered in San Diego, California. The Company is advancing the Hemopurifier®, an investigational extracorporeal immunotherapeutic platform designed to remove tumor-derived extracellular vesicles and enveloped viruses from circulation for potential applications in oncology, infectious disease, and other disease states. For more information, visit www.AethlonMedical.com and follow the Company on LinkedIn. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Forward-looking statements in this release include, among others, statements regarding: the investigational status and potential safety, feasibility, or utility of the Hemopurifier®; the Company's ability to initiate, enroll, conduct, and complete its clinical trials, including in Australia; the timing, scope, design, and potential outcomes or interpretation of such studies; the Company's ability to manufacture the Hemopurifier in sufficient quantities for clinical and potential future commercial use; the availability and adequacy of capital to support ongoing operations; statements regarding the Company's Ebola-related compassionate use activities and any resulting interest from public health organizations; the Company's collaborative research activities, including rheumatoid arthritis, chronic kidney disease, and other extracellular vesicle- associated conditions;  and the Company's ability to advance or expand its research programs in oncology, infectious diseases, and other conditions associated with extracellular vesicles. Such forward-looking statements are subject to significant risks and uncertainties, and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Aethlon's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors that may contribute to such differences include, without limitation, the fact that the cash on hand may not be sufficient to support operations for the next 12 months without additional financing, the Company's ability to raise additional capital on terms favorable to the Company, or at all; the Company's ability to successfully complete development of the Hemopurifier; the Company's ability to successfully demonstrate the utility and safety of the Hemopurifier in cancer and infectious diseases and in the transplant setting; the Company's ability to achieve and realize the anticipated benefits from operational and financial milestones; the Company's ability to maintain its Nasdaq listing, the Company's ability to obtain approval from the Ethics Committee of its third location in Australia, including on the timeline expected by the Company; the Company's ability to enroll additional patients in its oncology clinical trial in Australia, including on the timeline expected by the Company; the Company's ability to manage and successfully complete its clinical trials; the Company's ability to successfully manufacture the Hemopurifier in sufficient quantities for its clinical trials; unforeseen changes in regulatory requirements; the Company's collaborative research with UCSF Long Covid Clinic; and the Company's ability to further research potential applications of the Hemopurifier in other EV-associated diseases and other potential risks. The foregoing list of risks and uncertainties is illustrative but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2026, and in the Company's other filings with the Securities and Exchange Commission, including its Quarterly Reports on Form 10-Q. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances. Because the Hemopurifier® is an investigational device, its safety and effectiveness have not been established, and no conclusions should be drawn regarding clinical benefit. The observations contained in this release are from an early feasibility study and should not be interpreted as evidence of clinical benefit or safety beyond the study parameters. Company Contact:Jim FrakesChief Executive Officer and Chief Financial OfficerAethlon Medical, Inc. [email protected] Investor Contact:Susan NoonanS.A. Noonan Communications, [email protected] View original content:https://www.prnewswire.com/news-releases/aethlon-medical-reports-q1-fiscal-2027-results-and-progress-on-hemopurifier-program-302850290.html

SAN DIEGO, Aug. 5, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal first quarter ended June 30, 2026, at 4:15 p.m. ET on Thursday, August 13, 2026. Management will host a conference call on Thursday, August 13, 2026, at 4:30 p.m. ET to review financial results and recent corporate developments. Following management's formal remarks, there will be a question and answer session. Interested parties can register for the conference call by navigating to https://dpregister.com/sreg/10211144/104a3acc428. Please note that registered participants will receive their dial-in number upon registration. Interested parties without internet access or unable to pre-register may dial in by calling: PARTICIPANT DIAL IN (TOLL FREE): 1-844-836-8741 PARTICIPANT INTERNATIONAL DIAL IN: 1-412-317-5442 All callers should ask for the Aethlon Medical, Inc. conference call. A replay of the call will be available approximately one hour after the end of the call through September 13, 2026. The replay can be accessed via Aethlon Medical's website or by dialing 1-855-669-9658 (USA or Canada) or 1-412-317-0088 (international) or Canada toll free at 1-855-669-9658. The replay conference ID number is 6711524. About Aethlon and the Hemopurifier® Aethlon Medical is a medical therapeutic company focused on developing the Hemopurifier, a clinical stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and in pre-clinical studies, the Hemopurifier has demonstrated the removal of harmful exosomes from biological fluids, utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where exosomes may promote immune suppression and metastasis, and in life-threatening infectious diseases. The Hemopurifier is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption (IDE) application related to the treatment of life-threatening viruses that are not addressed with approved therapies. Additional information can be found at www.AethlonMedical.com. Forward Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. Risks and uncertainties include, but are not limited to, clinical trial outcomes, regulatory approvals, the ability to obtain additional financing, and market acceptance of the Company's products, as more fully described in the Company's filings with the Securities and Exchange Commission. These forward-looking statements are based upon Aethlon's current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances. Company Contact:Jim FrakesChief Executive Officer and Chief Financial OfficerAethlon Medical, Inc. [email protected] Investor Contact:Susan NoonanS.A. Noonan Communications, [email protected] View original content:https://www.prnewswire.com/news-releases/aethlon-medical-to-release-first-quarter-financial-results-and-host-conference-call-on-august-13-2026-302843685.html

This article first appeared on GuruFocus. Cash and Cash Equivalents: Approximately $5 million as of March 31, 2026. Net Proceeds Raised: Approximately $1.85 million through the at-the-market program subsequent to fiscal year-end. Operating Expenses: Declined 21.9% year-over-year to approximately $7.3 million. Operating Loss: Decreased to approximately $7.3 million for fiscal 2026 from $9.3 million in the prior fiscal year. Other Income: Approximately $142,000 for the fiscal year ended March 31, 2026, primarily from interest income. Net Loss: $7.2 million for the fiscal year ended March 31, 2026, compared to $13.4 million for the fiscal year ended March 31, 2025. Warning! GuruFocus has detected 6 Warning Signs with QYOUF. Is AEMD fairly valued? Test your thesis with our free DCF calculator. Release Date: June 10, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Aethlon Medical Inc (NASDAQ:AEMD) achieved important clinical research and intellectual property milestones during the fiscal year. The company successfully completed enrollment and treatment of participants in Cohort 2 of its Australian oncology trial with no safety concerns. Aethlon Medical Inc (NASDAQ:AEMD) is expanding the Hemopurifier's applications into additional disease areas through preclinical research. The company has maintained disciplined cost control, resulting in a 21.9% reduction in operating expenses year-over-year. Aethlon Medical Inc (NASDAQ:AEMD) strengthened its balance sheet by raising approximately $1.85 million in net proceeds through its at-the-market program. The company's cash and cash equivalents as of March 31, 2026, were approximately $5 million, which may limit long-term financial flexibility. Despite progress, the Hemopurifier platform is still in the early stages of clinical trials, with primary endpoints focused on safety rather than efficacy. The compassionate use protocol for Ebola is specific and limited to 20 patients at up to 10 centers, which may restrict broader application. Aethlon Medical Inc (NASDAQ:AEMD) experienced screen failures in its oncology trial due to patients not meeting inclusion or exclusion criteria. The company's net loss attributable to common stockholders was $7.2 million for the fiscal year ended March 31, 2026, indicating ongoing financial challenges. Q: Can you clarify the compassionate use protocol for Ebola and its current status? A: The compassionate use protocol is specific to Ebola, allowing treatment of up to 20 Ebola patients at 10 centers. It is separate from past emergency treatments for other conditions and remains open for enrollment. - James Frakes, CEO and CFO Q: Could you provide more details on the preclinical activities around rheumatoid arthritis and the timeline? A: We are testing platelet-derived extracellular vesicles (EVs) in healthy and rheumatoid arthritis plasma samples. This work is being done cost-effectively in-house. The aim is to publish peer-reviewed papers based on these findings. - Steven Larosa, Chief Medical Officer Q: What are the next steps for the preclinical activities, and how will you proceed with the data? A: We plan to publish peer-reviewed papers and present findings at medical meetings. This includes data from rheumatoid arthritis and chronic kidney disease samples, focusing on EV removal. - Steven Larosa, Chief Medical Officer Q: How is the interest in the Australian oncology trial, and what is the status of Cohort 3? A: There is strong engagement from the three sites, with active screening for participants. The first participant in Cohort 3 has been treated, and the interest remains high. - Steven Larosa, Chief Medical Officer Q: What are the efficacy endpoints for the current studies, and are there any notable findings? A: The primary endpoint is safety, with secondary endpoints including EV removal and T cell effects. Initial findings show positive changes in EVs and T cells, which will be further analyzed statistically at the study's end. - Steven Larosa, Chief Medical Officer Q: Are there any signals that the Hemopurifier may enhance therapies like KEYTRUDA or Opdivo? A: Initial data from the first cohort showed a reduction in EVs carrying PD-L1, which are linked to resistance to anti-PD-1 therapy. This is a positive signal that needs further confirmation. - Steven Larosa, Chief Medical Officer Q: Can you summarize the overall progress and direction of the Hemopurifier platform? A: Everything is progressing as expected, with positive signals in the right direction for the treated patients. We remain focused on advancing the platform through disciplined clinical execution. - Steven Larosa, Chief Medical Officer Q: What are the financial highlights from the fiscal year-end results? A: Operating expenses decreased by 21.9% to $7.3 million, and the net loss was reduced to $7.2 million. We have strengthened our balance sheet with $1.85 million raised post-fiscal year-end. - James Frakes, CEO and CFO For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Australian oncology study advances into Cohort 3 as enrollment continues Entered the third and final dosing cohort of the Australian oncology study, expanded the Hemopurifier intellectual property portfolio, and maintained a focus on managing operating expenses. Conference Call Today at 4:30 p.m. ET SAN DIEGO, June 10, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (Nasdaq: AEMD), a clinical-stage medical therapeutic company focused on developing products to treat cancer and life-threatening viral infections for which there is no treatment, today reported financial results for its fiscal year ended March 31, 2026, and provided an update on recent developments. Key Highlights Advanced the Australian oncology study through completion of the first two cohorts and entered the third and final dosing cohort, representing a key clinical milestone toward generating data to inform future development and dosing strategy. Recently treated the first participant in Cohort 3 at Royal North Shore Hospital in Australia. The participant completed three Hemopurifier treatments over a one-week period, marking continued enrollment momentum and execution of the study's final treatment arm. Advanced preclinical research evaluating Hemopurifier applications in additional disease areas, including rheumatoid arthritis and chronic kidney disease, supporting the expansion of the platform's potential addressable market beyond oncology and infectious disease. Continued to strengthen the intellectual property portfolio supporting the Hemopurifier platform, including the issuance of patents in the United States and Europe covering potential applications for long COVID and other coronavirus-related conditions, extending patent protection into the 2040s and enhancing long-term platform value. "Fiscal 2026 was a year of meaningful execution for Aethlon as we advanced our Australian oncology study through the first two cohorts and recently initiated Cohort 3. Advancement into the final cohort represents an important clinical milestone as we work toward generating data that may help define the optimal treatment regimen and guide future development decisions. We also strengthened the Hemopurifier platform through expansion of our intellectual property portfolio and advancement of preclinical research supporting potential applications beyond oncology. Combined with our continued focus on managing operating expenses, these achievements position us to pursue multiple value-creating opportunities across our clinical and research programs." said James Frakes, Chief Executive Officer and Chief Financial Officer of Aethlon Medical. Clinical Update Clinical Progress in Cancer Trial Enrollment and treatment of participants in Cohort 2 of the Australian oncology trial have been completed. An independent Data Safety Monitoring Board reviewed the data, identified no safety concerns based on its review of available data, and recommended advancing to the third and final cohort. Screening is actively underway at the three investigative sites for this final cohort where 3-6 participants will be treated with 3 Hemopurifier sessions during a 1-week period. The first participant in Cohort 3 of the study has been enrolled and received three Hemopurifier treatments without any device deficiencies or immediate complications and is now in the follow-up period. Successful enrollment and treatment of the first participant in Cohort 3 maintains the study's clinical momentum and moves the Company closer to completing enrollment and generating data from all planned dosing regimens. Serial Extracellular Vesicle and T cell measurements on participants in cohort 2 have been measured by the central lab at the University of Sydney. Formal statistical analyses comparing the effects of the three different Hemopurifier dosing regimens on these parameters will be performed by a CRO at the completion of the trial. This nine-to-18 patient study is designed to evaluate the safety and feasibility of the Hemopurifier treatments and determine the appropriate dosing in participants with solid tumors whose disease is stable or progressing while on a treatment that includes the anti-PD-1 agents, Keytruda® or Opdivo®. Other Recent Developments During fiscal 2026, we strengthened our intellectual property portfolio through the issuance of patents in both the United States and Europe covering 2 potential applications of the Hemopurifier for coronavirus-related conditions; excessive clotting known as coagulopathy during acute COVID-19 infection and symptoms of Long COVID. These patents extend protection for certain applications of the Hemopurifier into the 2040s. In addition, we advanced our preclinical extracellular vesicle (EV) research activities, including studies evaluating removal of EVs in plasma samples from patients with rheumatoid arthritis and chronic kidney disease. These efforts support the Company's ongoing evaluation of the Hemopurifier's potential applications across multiple disease categories and may create future opportunities to expand the platform into large markets characterized by significant unmet medical need. Separately, we continued our evaluation of Hemopurifier compatibility with a simplified blood treatment system being developed by Stavro Medical. Initial testing assessing flow rates and transfer of fluid through the Hemopurifier has been completed, and future studies evaluating removal of surrogate markers for extracellular vesicles by the Hemopurifier using the system are under consideration. We believe this approach could expand potential treatment settings for the Hemopurifier in the future and may improve the scalability and accessibility of treatment if successfully developed and validated. Subsequent to fiscal year-end, an interview published in IEEE Spectrum featuring Aethlon's Chief Medical Officer and a physician involved in the treatment of an Ebola virus disease patient with the Hemopurifier during the 2014 outbreak highlighted the Company's experience with Ebola treatment efforts. In connection with renewed public health interest surrounding recent Ebola outbreaks, we also confirmed the continued availability of our FDA-authorized expanded access (compassionate use) protocol and shared the protocol as well as past in vitro and in vivo data with organizations involved in global and U.S. emerging pathogen preparedness efforts, including the World Health Organization's R&D Blueprint expert panel and the National Emerging Special Pathogen Training and Education Center. Financial Results for the Fiscal Year Ended March 31, 2026 As of March 31, 2026, the Company had approximately $5.0 million in cash and cash equivalents, providing resources to support ongoing clinical and research activities. Subsequent to fiscal year-end, the Company strengthened its balance sheet by raising approximately $1.85 million in net proceeds through its at-the-market program. Consolidated operating expenses declined 21.9% year-over-year to approximately $7.3 million, reflecting continued expense discipline and operational efficiency while advancing the Company's clinical and research priorities compared to $9.3 million for the fiscal year ended March 31, 2025. The decrease was primarily due to $1.1 million reduction in payroll and related expenses, a $500,000 reduction in general and administrative expenses and a $400,000 reduction in professional fees. Consistent with the reduction in operating expenses, the operating loss for the fiscal year decreased to approximately $7.3 million for fiscal 2026 from $9.3 million in the prior fiscal year. Other income was approximately $142,000 for the fiscal year ended March 31, 2026, primarily reflecting interest income earned on cash balances, compared to other expense of approximately $4 million in the prior fiscal year. The prior-year amount included approximately $4.7 million of non-cash financing-related charges. Net loss attributable to our common stockholders was $7.2 million for the fiscal year ended March 31, 2026, compared to net loss of $13.4 million for the fiscal year ended March 31, 2025. The consolidated balance sheets for March 31, 2026, and March 31, 2025, and the consolidated statements of operations for the fiscal years ended March 31, 2026, and 2025, are included at the end of this release. Conference Call Management will host a conference call today, Wednesday, June 10, 2026, at 4:30 p.m. ET to review the Company's financial results and recent corporate developments. Following management's formal remarks, there will be a question-and-answer session. Interested parties can register for the conference call by navigating to https://dpregister.com/sreg/10209612/1042263e8ec. Please note that registered participants will receive their dial-in number upon registration. Interested parties without internet access or unable to pre-register may dial in by calling: PARTICIPANT DIAL IN (TOLL FREE): 1-844-836-8741PARTICIPANT INTERNATIONAL DIAL IN: 1-412-317-5442 All callers should ask for the Aethlon Medical, Inc. conference call. A replay of the call will be available approximately one hour after the end of the call through July 10, 2026. The replay can be accessed via Aethlon Medical's website or by dialing 1-855-669-9658 (USA or Canada) or 1-412-317-0088 (international) or Canada toll free at 1-855-669-9658. The replay conference ID number is 7883435. About the Hemopurifier® The Aethlon Hemopurifier is an investigational medical device designed to remove enveloped viruses and tumor-derived extracellular vesicles (EVs) from circulation. It is used extracorporeally with a blood pump and combines plasma separation, size exclusion, and affinity binding using a plant lectin resin that targets mannose-rich surfaces found on EVs and viruses. EVs released by solid tumors are believed to play a role in metastasis and the resistance to immunotherapies and chemotherapy. Removal of enveloped viruses and extracellular vesicles has been demonstrated in both in vitro studies and human subjects. The Hemopurifier holds a U.S. Food and Drug Administration Breakthrough Device Designation for: The treatment of individuals with advanced or metastatic cancer unresponsive to or intolerant of standard-of-care therapy; and the treatment of life-threatening viruses not addressed with approved therapies. About Aethlon Medical, Inc. Aethlon Medical, Inc. (Nasdaq: AEMD) is a clinical-stage medical device company headquartered in San Diego, California. Aethlon is advancing the Hemopurifier, to address unmet needs in oncology and infectious disease, using a novel platform designed to selectively remove circulation pathogenic targets from biologic fluids. For more information, visit www.AethlonMedical.com and follow the Company on LinkedIn. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Forward-looking statements in this release include, among others, statements regarding: the investigational status and potential safety, feasibility, or utility of the Hemopurifier®; the Company's ability to initiate, enroll, conduct, and complete its clinical trials, including in Australia; the timing, scope, design, and potential outcomes or interpretation of such studies; the Company's ability to manufacture the Hemopurifier in sufficient quantities for clinical and potential future commercial use; the availability and adequacy of capital to support ongoing operations; statements regarding the Company's Ebola-related compassionate use activities and any resulting interest from public health organizations; the Company's collaborative research activities, including rheumatoid arthritis, chronic kidney disease, and other extracellular vesicle- associated conditions; and the Company's ability to advance or expand its research programs in oncology, infectious diseases, and other conditions associated with extracellular vesicles. Such forward-looking statements are subject to significant risks and uncertainties, and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Aethlon's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors that may contribute to such differences include, without limitation, the fact that the cash on hand may not be sufficient to support operations for the next 12 months without additional financing, the Company's ability to raise additional capital on terms favorable to the Company, or at all; the Company's ability to successfully complete development of the Hemopurifier; the Company's ability to successfully demonstrate the utility and safety of the Hemopurifier in cancer and infectious diseases and in the transplant setting; the Company's ability to achieve and realize the anticipated benefits from operational and financial milestones; the Company's ability to maintain its Nasdaq listing, the Company's ability to obtain approval from the Ethics Committee of its third location in Australia, including on the timeline expected by the Company; the Company's ability to enroll additional patients in its oncology clinical trial in Australia, including on the timeline expected by the Company; the Company's ability to manage and successfully complete its clinical trials; the Company's ability to successfully manufacture the Hemopurifier in sufficient quantities for its clinical trials; unforeseen changes in regulatory requirements; the Company's collaborative research with UCSF Long Covid Clinic; and the Company's ability to further research potential applications of the Hemopurifier in other EV-associated diseases and other potential risks. The foregoing list of risks and uncertainties is illustrative but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2026, and in the Company's other filings with the Securities and Exchange Commission, including its Quarterly Reports on Form 10-Q. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances. Because the Hemopurifier® is an investigational device, its safety and effectiveness have not been established, and no conclusions should be drawn regarding clinical benefit. The observations contained in this release are from an early feasibility study and should not be interpreted as evidence of clinical benefit or safety beyond the study parameters. Company Contact:Jim FrakesChief Executive Officer and Chief Financial OfficerAethlon Medical, Inc. [email protected] Investor Contact:Susan NoonanS.A. Noonan Communications, [email protected] View original content:https://www.prnewswire.com/news-releases/aethlon-medical-announces-fiscal-year-end-march-31-2026-financial-results-and-corporate-update-302795934.html

Image source: The Motley Fool. June 10, 2026, 4:30 p.m. ET Chief Executive Officer and Chief Financial Officer — James Frakes Chief Medical Officer — Steven LaRosa Need a quote from a Motley Fool analyst? Email [email protected] James Frakes: Thank you, operator, and good afternoon, everyone. Welcome to Aethlon Medical's Fiscal Year-End March 31, 2026, Earnings Conference Call. My name is Jim Frakes, and I'm the Chief Executive Officer and Chief Financial Officer of Aethlon Medical. At 4:15 p.m. Eastern Time today, Aethlon Medical released financial results for its fiscal year ended March 31, 2026. If you have not seen or received Aethlon Medical's earnings release, please visit the Investors page at www.aethlonmedical.com to view it. Following this introduction and the reading of the company's forward-looking statement disclaimer, Dr. Stephen LaRosa, our Chief Medical Officer, and I will provide an overview of Aethlon's strategy and recent developments. I will then make some brief remarks on Aethlon's financials. We will then open up the call for the Q&A session. Before we start the business portion of the call, please note that the news release today and this call contain forward-looking statements within the meaning of the Securities Act of 1933 as amended, and the Securities Exchange Act of 1934 as amended. The company cautions you that any statement that is not a statement of historical fact is a forward-looking statement. These statements are based on expectations and assumptions as of the date of this conference call. Such forward-looking statements are subject to significant risks and uncertainties, and actual results may differ materially from the results anticipated in the forward-looking statements. Factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption Risk Factors in the company's annual report on Form 10-K for the fiscal year ended March 31, 2026. The company's most recent quarterly report on Form 10-Q and in the company's other filings with the Securities and Exchange Commission. Except as may be required by law, the company does not intend nor does it undertake any duty to update this information to reflect future events or circumstances. Now I would like to begin by highlighting progress during the fiscal year ended March 31 going on through the first part of June as we continue to execute against our strategy of advancing the Hemopurifier platform while maintaining disciplined cost control. During the period, we achieved important clinical research and intellectual property milestones. We continue to advance our oncology program while also expanding our evaluation of Hemopurifier applications into additional disease areas through preclinical research. These efforts reflect our broader objective of establishing the Hemopurifier as a platform technology with potential applications across multiple serious and life-threatening conditions. Taken together, these achievements demonstrate continued execution against our key priorities of clinical development, platform expansion, intellectual property growth and disciplined resource management. And now I will turn the call over to Dr. Larosa who will cover updates on the Australian oncology trial and under our R&D efforts. Steve? Steven Larosa: Thank you, Jim. Enrollment and treatment of participants in cohort 2 of our Australian oncology trial have been completed. As a reminder, 3 participants in Cohort 2 received 2 4-hour hemopreia fire treatments during a 1-week treatment period. An independent data safety monitoring board reviewed the data, identified no safety concerns and recommended advancing to the third and final cohort of the study with no protocol modifications. Screening is actively underway at all 3 investigative sites for this final cohort where 3 to 6 participants will be treated with 3 Hemopurifier sessions during a 1-week period. The first participant in cohort 3 of the study has been enrolled, and received 3 Hemopurifier treatments without any device deficiencies or immediate complications and is now in the safety follow-up period. Cereal extracellular vesicle and T cell measurements on participants in cohort 2 have been measured by the central lab at the University of Sydney. Formal statistical analyses comparing the effects of the 3 different Hemopurifier dosing regimens on these parameters will be performed by our CRO at the completion of the trial. As a reminder, this is a 9 to 18 patient study designed to evaluate the safety and the feasibility of the Hemopurifier treatments and determine an appropriate dosing interval and participants with solid tumors whose disease is stable or progressing well on a treatment that includes anti-PD-1 KEYTRUDA or Opdivo. Segueing now to our preclinical activities. We are advancing our preclinical extracellular vesicle research activities, including studies evaluating removal of EVs and plasma samples from patients with rheumatoid arthritis and chronic kidney disease. Platelet-derived extracellular vesicles in their cargo have been noted to play a pathogenic role in rheumatoid arthritis. EVs in patients with chronic kidney disease have been demonstrated to contribute to congestive heart failure in this population. These efforts support the concept of a pipeline within a single device with EV removal as the primary mechanism of action. Separately, we continued our evaluation of the Hemopurifier compatibility with a simplified blood pump system developed by Sabre Medical. Initial testing assessed flow rates and transfer of died fluid to the Hemopurifier. These assessments have been completed and were successful. Future studies being considered right now, including the use of blood or plasma and removal of surrogate markers for extracellular vesicles by the Hemopurifier using this blood pump system. We believe that freeing the Hemopurifier up from a dialysis machine, dialysis unit and a large double lumen dialysis catheter would improve the number of physicians able to perform the Hemopurifier treatment and increase the number of places where such a treatment could be performed. For the patient, this could translate into having a less invasive vascular catheter placed and being able to receive their treatment in their therapeutic home. Aethlon Medical is closely monitoring the evolving outbreak of the Bundabouzhou species of Ebola in the Democratic Republic of the Congo and Uganda. The company has previously published in vitro removal data on the Marburg and Zier species of Ebola from both cell culture fluid and plasma by a miniature version of the Hemopurifier. During the 2014 Zier outbreak, a single 6.5-hour Hemopurifier treatment of a critically ilebola patient with multi-organ failure was associated with a 2 log reduction in viral load and clinical recovery. In December 2014, the FDA approved a compassionate use protocol as a supplement to our open IDE for life-threatening viral infections for which there is no treatment. This compassionate use protocol allows for the treatment of up to 20 subjects at up to 10 institutions in the U.S. Recent interactions with the FDA has confirmed that this protocol remains open for enrollment. Aethlon has shared the above information, with both the World Health Organization's R&D Boopprint expert panel, as well as the national emerging special pathogens training and education center known as ETEC, who works closely with the 13 U.S. regional special pathogen treatment centers, that would treat a patient with Ebola in the U.S. should it happen. With that, I'll turn the call back over to Jim for the financial discussion and questions. James Frakes: Thanks, Steve, and good afternoon again, everyone. Turning briefly to the financials. As of March 31, 2026, we had approximately $5 million in cash and cash equivalents which provides resources to support ongoing clinical and research activities. Subsequent to fiscal year-end, we further strengthened our balance sheet by raising approximately $1.85 million in net proceeds through our at-the-market program. Turning to some high-level expense analysis. Our consolidated operating expenses declined 21.9% year-over-year to approximately $7.3 million, reflecting continued expense discipline and operational efficiency, while advancing our clinical and research priorities. That compares to a $9.3 million of operating expenses in the fiscal year ended March 31, 2025. The decrease was primarily due to a $1.1 million reduction in payroll and related expenses, a $500,000 reduction in general and administrative expenses and a $400,000 reduction in professional fees. Consistent with the reduction in operating expenses, the operating loss for the fiscal year decreased to approximately $7.3 million for fiscal 2026 from $9.3 million in the prior fiscal year. You can find more detail on these expense changes in our 10-K, which breaks down specific drivers by category. Our other income was approximately $142,000 for the fiscal year ended March 31, 2026, primarily reflecting interest income earned on cash balances that compares to other expense of approximately $4 million in the prior fiscal year. The prior year amount included approximately $4.7 million of noncash financing related charges. So overall, our net loss attributable to our common stockholders was $7.2 million for the fiscal year ended March 31, 2026. And compared to a net loss of $13.4 million for the fiscal year ended March 31, 2025. We included these earnings results and related commentary in our press release issued this afternoon. The release also included the balance sheet for March 31, 2026 and 2025 and the consolidated statements of operations for the fiscal years ended March 31, 2026, and 2025. We will file our annual report on Form 10-K following this call. Our next earnings call for the fiscal first quarter ending June 30, 2026. We'll coincide with the filing of our quarterly report on Form 10-Q in August 2026. And now we would be happy to answer any questions that you may have. Operator, please open the call for questions. Operator: [Operator Instructions] The first question comes from Marla Marin with Zacks. Marla Marin: So a lot going on. So just a couple of housekeeping questions. I want to get back to something that I think you said, Jim, the compassionate use protocol, which is still open. Can you refresh us in terms of your -- it would seem to me based on my recollection of I know you treated some seriously ill cove patients, but it would seem to me that you're well below that threshold that you cited of the number of potential patients to be treated and the number of medical centers. James Frakes: I believe the Ebola protocol is relevant only to Ebola. So it would be up to 20 patients -- Ebola patients at 10 centers. Steven Larosa: No, that compassionate protocol specific to Ebola and it's 20 patients at up to 10 centers. Marla Marin: Okay. Got it. So it's completely separate from the patients that you had treated in the past under emerge. Unknown Executive: Yes. Marla Marin: Okay. Got it. Unknown Executive: That is correct. That is correct. Marla Marin: Okay. Good. Can you give us a little more color on how you're planning to approach the preclinical activities around rheumatoid arthritis, is that I'm guessing that this is something that will be done in a very cost-efficient manner because that's what you've been doing in terms of expanding or extending the research activities outside the current ongoing trial. But can you give us some color and also some sense of what the time line there is? James Frakes: You want to take that? Sure. Steven Larosa: So Marla, rheumatoid arthritis is just 1 of the many diseases where platelet-derived EV, a sizable percentage of the EV population in our blood. -- is implicated in the disease. What we did is the first instance is test healthy plasma to look for platelet removal of EVs, platelet drive BVs. And we did that in a single large volume healthy plasma sample. We subsequently purchased in a cost-effective way, a couple of additional healthy plasma samples. And now we are purchasing large volume rheumatoid arthritis samples. And those are all being run at our lab with the focus on the platelet-derived EVs and the mine. So that work is currently underway. And with the chronic kidney just finish the wells I mentioned chronic kidney disease. There's been recent publications that these patients have EVs that caused congestive heart failure, which is a huge source of morbidity and mortality in this population. So we have purchased small samples of chronic kidney disease plasma. We're testing them for binding to the resin in our device. And again, that work is being done in-house as well. Marla Marin: And -- how should we think about except there? Because in the past, I know you've contributed to working on peer reviews papers, you've presented at different medical presentations. So how should we think about next steps depending upon the outcome of the testing that you're doing now? Steven Larosa: Yes, sure. So the -- we published a preprint in 1 of the preprint servers on removal of platelet-derived EVs from a single healthy plasma specimen. The feedback we received is we needed to run more samples and that we need to also go into a relevant disease sample. So with that in mind, we got the additional healthy plasma samples, and we got the rheumatoid arthritis sand we think that this will be the data needed to satisfy the reviewers and turn, but have, in addition to a preprint and actually reviewed publication on the subject with respect to our device. Same thing with the CKD, chronic kidney disease samples, we'll look at binding to our resin, and we would then plan on turning that into an abstract at a medical meeting and a peer-reviewed publication. Again, filling -- trying to fill the preclinical pipeline. Marla Marin: Right. Got it. Got it. and building your database, in the most cost-effective way that you can. Is that the right way to think about it? Steven Larosa: Yes. Yes. I think that's a good way to say it. Marla Marin: Okay. And then last question from me. So you've treated the first participant in cohort 3. And I think at your last conference call, you said you had you were very pleased with the interest that you had seen in participating in the trial. Is that still something that's operating in terms of moving on to treating the next participant? Steven Larosa: Yes. No, we've seen good engagement and commitment from our 3 sites in terms of screening activity. So that remains a positive, bodes well. We did have a few patients that became screen failures for not meeting an inclusion or exclusion criteria. That happens in every study, unavoidable. So -- but the most important thing for me is that the engagement is there and the activity is there. Operator: The next question comes from Anthony Vendetti with Mastin Group. Anthony Vendetti: Yes. Thanks. So just in terms of the efficacy, any endpoints you're looking for or readout on an efficacy standpoint because I know obviously the first studies are safety -- but you -- but what are you looking for in terms of efficacy? And are you able to report on those other than internally know about it? Are you able to publish that data. Steven Larosa: Yes. So remember, the primary endpoint for this study is safety. Secondary endpoint is surrogate markers looking at the Hemopurifiers activity, and those would be EV removal, extracellular vesicle removal and effects on T cells, including antitumor T cells. We previously reported on some qualitative observations from the first cohort, and those are in a prior press release, where we saw some changes in EVs and T cells in the right direction. As I just said, we just received measurements from Cohort 2. But the big thing that will occur is at the end of the study, there will be a formal statistical analysis looking at those dosing regimens between the different dosing regimens. And that will look at magnitude of EV decreases and duration of EV decreases as comparing the 3 strategies and again, magnitude and duration of positive effects on T cells. Those will be the major readouts. The study is not randomized and is small such that clinical outcomes are not a primary outcome or a secondary outcome of the study. It's just way too small for such -- for clinical efficacy. Anthony Vendetti: Right. Right. No, of course, at this stage Yes. Certainly for statistical significance in terms of clinical efficacy, but nonetheless, if they're doing well and you're able to show that, even though that's not the primary endpoint, that's always encouraging. What about any signals suggesting that the Hemopurifier may enhance the therapies like KEYTRUDA or Opdivo. Steven Larosa: Yes. I would just call your attention to that prior press release that shows that the EVs, including tumor-derived EVs went down in the first cohort and that there were improvements in T cells and antitumor T cells in the first cohort. Anthony Vendetti: Okay. And then any biomarkers or exosome-related findings that have emerged as well, I guess, the EVs is what you're talking about? Steven Larosa: Yes. In the first cohort of particular interest to us was that EVs carrying PDL surface went down during the treatment. These particular population of EVs have been implicated as a cause of resistance to anti-PD-1 therapy. So the fact that they went down with treatment, again, at least in the first cohort was a positive signal that will have to be corroborated, confirmed in the subsequent cohorts and the magnitude and duration will have to be examined, but that was a particular interest to me at least. Anthony Vendetti: Okay. So far, to sum it up, if I could do so, everything is moving in the direction you would want it to be moving in terms of what you're seeing so far with the patients that have been treated. Steven Larosa: Correct. Anthony Vendetti: Okay. Thank you very much. I'll hop back in the queue.. Operator: The next question comes from Jeremy Perlman with Maxim Group. Jeremy Pearlman: Yes, I think that was -- I didn't dial in. I think the operator will action that. I'm sorry, Anthony, you already asked the questions. Operator: This concludes our question-and-answer session. I would like to turn the conference back over to Jim Frick for any closing remarks. Please go ahead. James Frakes: Thank you. In closing, we remain focused on advancing the Hemopurifier platform through disciplined clinical execution and careful capital management. We appreciate your continued interest and support and look forward to speaking with you in August. Thank you very much. Goodbye. Operator: The conference has now concluded. Thank you for attending today's presentation. You may now disconnect. Before you buy stock in Aethlon Medical, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Aethlon Medical wasn’t one of them. The 10 stocks that made the cut are built for long-term growth and could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $439,038!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,277,804!* That performance is why people listen. With a track record of beating the S&P 500 by nearly 5x, Stock Advisor offers a distinct advantage. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built for the long haul. See the 10 stocks » *Stock Advisor returns as of June 10, 2026. This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Aethlon (AEMD) Q4 2026 Earnings Transcript was originally published by The Motley Fool

SAN DIEGO, June 2, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal year end March 31, 2026, at 4:15 p.m. ET on Wednesday, June 10, 2026. Management will host a conference call on Wednesday, June 10, 2026, at 4:30 p.m. ET to review financial results and recent corporate developments. Following management's formal remarks, there will be a question and answer session. Interested parties can register for the conference call by navigating to https://dpregister.com/sreg/10209612/1042263e8ec. Please note that registered participants will receive their dial-in number upon registration. Interested parties without internet access or unable to pre-register may dial in by calling: PARTICIPANT DIAL IN (TOLL FREE): 1-844-836-8741PARTICIPANT INTERNATIONAL DIAL IN: 1-412-317-5442 All callers should ask for the Aethlon Medical, Inc. conference call. A replay of the call will be available approximately one hour after the end of the call through July 10, 2026. The replay can be accessed via Aethlon Medical's website or by dialing 1-855-669-9658 (USA or Canada) or 1-412-317-0088 (international) or Canada toll free at 1-855-669-9658. The replay conference ID number is 7883435. About Aethlon and the Hemopurifier®Aethlon Medical is a medical therapeutic company focused on developing the Hemopurifier, a clinical stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and in pre-clinical studies, the Hemopurifier has demonstrated the removal of harmful exosomes from biological fluids, utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where exosomes may promote immune suppression and metastasis, and in life-threatening infectious diseases. The Hemopurifier is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption (IDE) application related to the treatment of life-threatening viruses that are not addressed with approved therapies. Additional information can be found at www.AethlonMedical.com. Forward Looking StatementsThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. Risks and uncertainties include, but are not limited to, clinical trial outcomes, regulatory approvals, the ability to obtain additional financing, and market acceptance of the Company's products, as more fully described in the Company's filings with the Securities and Exchange Commission. These forward-looking statements are based upon Aethlon's current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances. Company Contact:Jim FrakesChief Executive Officer and Chief Financial OfficerAethlon Medical, Inc. [email protected] Investor Contact:Susan NoonanS.A. Noonan Communications, [email protected] View original content:https://www.prnewswire.com/news-releases/aethlon-medical-to-release-fiscal-year-end-financial-results-and-host-conference-call-on-june-10-2026-302787553.html

This article first appeared on GuruFocus. Release Date: February 12, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Aethlon Medical Inc (NASDAQ:AEMD) reported progress in their Australian oncology trial, with successful completion of the first cohort and ongoing treatments in the second cohort. The company is expanding its extracellular vesicle (EV) research platform, supporting the hemopurifier as a potential multi-indication therapeutic. Aethlon Medical Inc (NASDAQ:AEMD) is advancing work on hemopurifier compatibility with a simplified blood treatment system, which could expand clinical and commercial flexibility. The company has achieved sustained operating expense reductions on a year-to-date basis compared to the prior year. Aethlon Medical Inc (NASDAQ:AEMD) has a cash balance of approximately $7 million as of December 31, 2025, indicating a stable financial position. Consolidated operating expenses for the quarter increased by 13.6% compared to the same period last year, primarily due to higher payroll and related costs. The operating loss for the quarter increased to $2.06 million compared to $1.81 million in the prior year period. Interest income earned on cash balances was lower than the previous year, at $44,000 compared to $60,000. The company is still in the early stages of its oncology trial, with the third cohort yet to be initiated, indicating that significant progress is still needed. There are potential regulatory hurdles and compatibility tests required for the integration of the hemopurifier with the new SLAMB SAA system, which could delay future developments. Warning! GuruFocus has detected 2 Warning Sign with AEMD. Is AEMD fairly valued? Test your thesis with our free DCF calculator. Q: You've moved on in the trial to cohort 2. Can you confirm that participants are involved in the trial for the same length of time as cohort 1? A: Yes, the follow-up period is the same. The difference is that in cohort 2, participants receive two hemo purifier treatments instead of one, typically on a Monday and Friday. This allows us to observe the kinetics of EV numbers between treatments and assess if two treatments lead to more lasting effects on EVs and T cells. - Dr. Steven LaRosa, Chief Medical Officer Q: Can you explain the potential impact of connecting the hemo purifier to the SLAM system? A: The SLAM system uses a smaller, less invasive catheter compared to the current large dialysis catheter. This could allow treatments to be administered in oncology units or infusion centers, rather than dialysis units, making it less invasive for patients and more integrated into their care. - Dr. Steven LaRosa, Chief Medical Officer Q: How are you managing costs while advancing pre-clinical research, such as in long COVID? A: We are keeping costs down by obtaining samples for minimal shipping costs, conducting work in-house with our small scientific staff, and limiting work by outside labs. This approach allows us to advance research while maintaining cost-effectiveness. - Jim Frakes, CEO and CFO Q: What is the timeline for the data safety monitoring board's decision on moving to cohort 3 in the oncology trial? A: The third patient in cohort 2 will be treated by the end of February, and the data safety monitoring board meeting is expected in late March. Historically, decisions have been made within a day of the meeting. - Dr. Steven LaRosa, Chief Medical Officer Q: Is there a need to conduct cohort 3, or could cohort 2 provide sufficient data? A: Based on Mayo Clinic data, we believe it's important to investigate three treatments per week, as it could potentially be superior to two treatments in terms of EV removal and T cell effects. It would be premature to stop at two without further investigation. - Dr. Steven LaRosa, Chief Medical Officer For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Clinical and research programs continue to advance, supported by year-to-date cost efficiencies Conference Call Today at 4:30 p.m. ET SAN DIEGO, Feb. 12, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal third quarter ended December 31, 2025, and provided an update on recent developments. Key Highlights Maintained Nasdaq Listing: Continued compliance with Nasdaq listing requirements, with all prior compliance matters remaining resolved. Clinical Progress: Cohort 2 of the Australian oncology trial is actively progressing, reflecting continued clinical execution. Scientific Advancement: Continued advancement of the Company's preclinical extracellular vesicle (EV) research platform, including Long COVID data published on bioRxiv and submitted for peer review, supporting the Hemopurifier's potential as a multi-indication therapeutic approach and a "pipeline within a single device". Technology Development: Continued evaluation of Hemopurifierﾮ (HP) compatibility with a simplified blood treatment system to support broader potential clinical application over time. Operational Efficiency: Maintained disciplined cost controls, resulting in lower year-to-date operating expenses compared to prior year. Clinical and Corporate Update Clinical Progress in Cancer Trial Enrollment and treatment of participants in Cohort 2 of the Australian oncology trial is actively underway, building on Cohort 1, which demonstrated favorable directional improvements in extracellular vesicle and immune cell numbers, as well as safety and tolerability. This nine-to-18 patient study is designed to evaluate the safety and feasibility of the Hemopurifier treatments and determine the appropriate dosing in participants with solid tumors whose disease is stable or progressing while on a treatment that includes the anti-PD-1 agents, Keytrudaﾮ or Opdivoﾮ. Technology Development: Under a Material Transfer Agreement (MTA), Stavro is evaluating the compatibility of the Hemopurifier with their SLAMB system, a simplified blood treatment platform. We believe this research may support future Hemopurifier use in oncology units and infusion centers without requiring a large dialysis catheter, dialysis machines, or supervising nephrologist. Scientific Advancement: The Aethlon R&D team continues to build on our pre-clinical Long COVID research, which demonstrated that the GNA affinity resin binds EVs from Long COVID patient samples and reduces microRNAs associated with immune dysregulation. These findings were published on bioRxiv and have been submitted for consideration in a peer-reviewed journal. We are also exploring other cargo in these EVs, that may be removed by the Hemopurifier. EVs, including platelet-derived EVs, have been implicated in a range of diseases beyond cancer, such as Lupus, Rheumatoid arthritis, Systemic Sclerosis, Multiple Sclerosis, Cardiovascular Diseases, Sepsis and ALS. Aethlon previously published preclinical data demonstrating removal of platelet derived EVs from healthy plasma by the Hemopurifier and plan to extend this work by investigating the removal of platelet-derived EVs and microRNAs by the Hemopurifier in plasma from patients with select indications. We believe this work reflects the potential of the Hemopurifier as "a pipeline within a single device." Operational Achievements Operating expenses declined 26.9% during the nine months ended December 31, 2025, reflecting the Company's ongoing efforts to optimize costs while advancing its clinical and research programs. "We remain committed to advancing our clinical programs and research initiatives with operational discipline," said James Frakes, CEO and CFO of Aethlon Medical. "Recent progress in our trials, research collaborations, and technology development continues to move us closer to delivering therapeutic solutions for cancer and life-threatening infectious diseases." Financial Results for the Fiscal Third Quarter Ended December 31, 2025 As of December 31, 2025, Aethlon had a cash balance of approximately $7.0 million. Consolidated operating expenses for the three months ended December 31, 2025 were approximately $2.06 million, up $250,000, or 13.6%, from $1.81 million in the same period in 2024. The increase was primarily driven by higher payroll and related costs, which rose by approximately $367,000, partially offset by $75,000 decrease in general and administrative expenses, primarily due to lower clinical trial costs, and an approximate $45,000 decrease in professional fees primarily due to reduced investor relations expenses. As a result, the operating loss for the quarter increased to $2.06 million compared to $1.81 million in the prior year period. Other income, primarily interest income earned on cash balances, totaled $44,000 for the three months ended December 31, 2025, compared to $60,000 in the prior-year period. Financial Results for the Nine Months Ended December 31, 2025 Consolidated operating expenses for the nine months ended December 31, 2025 were approximately $5.36 million compared to approximately $7.34 million for the same period in 2024. This decrease of approximately $1.98 million, or 26.9%, in the 2025 period was due to decreases in payroll and related expenses of approximately $1.09 million, general and administrative expenses of $527,000 and professional fees of $361,000. The consolidated balance sheets for December 31, 2025 and March 31, 2025, along with the consolidated statements of operations for the three and nine months ended December 31, 2025 and 2024, are included at the end of this release. Conference Call Management will host a conference call today, Thursday, February 12, 2026, at 4:30 p.m. ET to review the Company's financial results and recent corporate developments. Following management's formal remarks, there will be a question and answer session. Interested parties can register for the conference call by navigating to https://dpregister.com/sreg/10206585/1034a255186. Please note that registered participants will receive their dial-in number upon registration. Interested parties without internet access or unable to pre-register may dial in by calling: PARTICIPANT DIAL IN (TOLL FREE): 1-844-836-8741 PARTICIPANT INTERNATIONAL DIAL IN: 1-412-317-5442 All callers should ask for the Aethlon Medical, Inc. conference call. A replay of the call will be available approximately one hour after the end of the call through March 12, 2026. The replay can be accessed via Aethlon Medical's website or by dialing 1-855-669-9658 (USA or Canada) or 1-412-317-0088 (international) or Canada toll free at 1-855-669-9658. The replay conference ID number is 3024961. About the Hemopurifierﾮ The Aethlon Hemopurifier is an investigational medical device designed to remove enveloped viruses and tumor-derived extracellular vesicles (EVs) from circulation. It is used extracorporeally with a blood pump and combines plasma separation, size exclusion, and affinity binding using a plant lectin resin that targets mannose-rich surfaces found on EVs and viruses. EVs released by solid tumors are believed to play a role in metastasis and the resistance to immunotherapies and chemotherapy. Removal of enveloped viruses and extracellular vesicles has been demonstrated in both vitro studies and human subjects. The Hemopurifier holds a U.S. Food and Drug Breakthrough Device Designation for: The treatment of individuals with advanced or metastatic cancer unresponsive to or intolerant of standard-of-care therapy; and the treatment of life-threatening viruses not addressed with approved therapies. About Aethlon Medical, Inc. Aethlon Medical, Inc. (Nasdaq: AEMD) is a clinical-stage medical device company headquartered in San Diego, California. Aethlon is advancing the Hemopurifier, to address unmet needs in oncology and infectious disease, using a novel platform designed to selectively remove circulation pathogenic targets from biologic fluids. For more information, visit www.AethlonMedical.com and follow the Company on LinkedIn. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Forward-looking statements in this release include, among others, statements regarding: the investigational status and potential safety, feasibility, or utility of the Hemopurifierﾮ; the Company's ability to initiate, enroll, conduct, and complete its clinical trials, including in Australia s; the timing, scope, design, and potential outcomes or interpretation of such studies; the Company's ability to manufacture the Hemopurifier in sufficient quantities for clinical and potential future commercial use; the availability and adequacy of capital to support ongoing operations; and the Company's ability to advance or expand its research programs in oncology, infectious diseases, and other conditions associated with extracellular vesicles. Such forward-looking statements are subject to significant risks and uncertainties, and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Aethlon's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors that may contribute to such differences include, without limitation, the fact that the cash on hand may not be sufficient to support operations for the next 12 months without additional financing, the Company's ability to raise additional capital on terms favorable to the Company, or at all; the Company's ability to successfully complete development of the Hemopurifier; the Company's ability to successfully demonstrate the utility and safety of the Hemopurifier in cancer and infectious diseases and in the transplant setting; the Company's ability to achieve and realize the anticipated benefits from operational and financial milestones; the Company's ability to maintain its Nasdaq listing, the Company's ability to obtain approval from the Ethics Committee of its third location in Australia, including on the timeline expected by the Company; the Company's ability to enroll additional patients in its oncology clinical trial in Australia, including on the timeline expected by the Company; the Company's ability to manage and successfully complete its clinical trials; the Company's ability to successfully manufacture the Hemopurifier in sufficient quantities for its clinical trials; unforeseen changes in regulatory requirements; the Company's collaborative research with UCSF Long Covid Clinic; and the Company's ability to further research potential applications of the Hemopurifier in other EV-associated diseases and other potential risks. The foregoing list of risks and uncertainties is illustrative but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2025, and in the Company's other filings with the Securities and Exchange Commission, including its Quarterly Reports on Form 10-Q. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances. Because the Hemopurifierﾮ is an investigational device, its safety and effectiveness have not been established, and no conclusions should be drawn regarding clinical benefit. The observations contained in this release are from an early feasibility study and should not be interpreted as evidence of clinical benefit or safety beyond the study parameters. Company Contact: Jim Frakes Chief Executive Officer and Chief Financial Officer Aethlon Medical, Inc. [email protected] Investor Contact: Susan Noonan S.A. Noonan Communications, LLC [email protected] View original content:https://www.prnewswire.com/news-releases/aethlon-medical-announces-fiscal-q3-2026-financial-results-and-corporate-update-302685564.html

Progress in the Australian oncology trial is driven by a new patient recruitment strategy utilizing online advertising and phone pre-screening to build a participant pool. The Hemopurifier is being positioned as a 'pipeline within a single device' by exploring its ability to remove extracellular vesicles (EVs) across oncology, Long COVID, and autoimmune indications. Management is evaluating compatibility with the SLAMB system to transition the Hemopurifier from invasive dialysis-based administration to simpler, less-invasive infusion center settings. Operational performance is characterized by significant year-to-date cost reductions of 27% achieved through disciplined payroll and professional fee management. The scientific rationale for the current oncology study was validated through peer-reviewed publication in BMJ Open, supporting the mechanism of EV removal to improve natural immune response. Management targets late March 2026 for a Data Safety Monitoring Board (DSMB) meeting to review safety data from the second cohort of the oncology trial. The transition to the third and final cohort, involving three treatments per week, is contingent on DSMB recommendation and is tentatively planned for April 2026. Future R&D will focus on examining platelet-derived EV and microRNA removal in disease-specific plasma to broaden the therapeutic application of the Hemopurifier. The company assumes that demonstrating compatibility with simplified pump systems will eventually remove the requirement for supervising nephrologists and specialized dialysis units. Cash balance of approximately $7 million as of December 31, 2025, supports ongoing clinical and research activities. Quarterly operating loss increased to $2.06 million due to higher payroll costs, though this was partially offset by lower clinical trial expenses. The company is intentionally limiting the use of outside labs for Long COVID and EV research to maintain strict cost control while advancing preclinical data. Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. Management explained that increasing to two treatments per week allows them to observe the kinetics of EV numbers between sessions. The goal is to determine if more frequent treatments lead to more long-lasting effects on T cells compared to the single-treatment cohort. The system would replace large 'garden hose' dialysis catheters with thin PICC lines, significantly reducing patient invasiveness. It would allow treatments to occur in oncology units or infusion centers, integrating the device into the patient's existing 'therapeutic home' rather than a dialysis ward. Aethlon has already established a 'queue' of potential participants for the third cohort, which should allow for rapid enrollment once the DSMB gives approval. Current protocols prevent signing consent for new patients until the trial officially advances to the next stage. Management confirmed they will not return to clinical sites in India, choosing to remain 'highly focused' on the Australian trial to avoid expense and distraction. The CEO noted that running multiple safety feasibility trials in different regions could complicate the eventual transition to a PMA trial. One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.